Air Liquide has today closed the sale of its subsidiary CRYOPDP to French private equity firm Hivest Capital Partners.

The sale completion follows the original agreement announced on 2nd March (2020).

Read more: Air Liquide in exclusive negotiations to sell subsidiary

The decision illustrates Air Liquide’s strategy to regularly review its asset portfolio in order to focus on key businesses and geographies to maximise its performances.

Headquartered in France, CRYOPDP aims to improve the health of people around the world by providing global innovative temperature-controlled logistics solutions to the Clinical Research and Cell & Gene Therapy Communities.